Results 81 to 90 of about 5,890 (202)

COMPARISON OF EFFICACY OF ORAL FLUCONAZOLE WITH INTRAMUSCULAR MEGLUMINE ANTIMONIATE IN TREATMENT OF CUTANEOUS LEISHMANIASIS

Pakistan Armed Forces Medical Journal, 2015
Objective:  To compare the efficacy of oral fluconazole with intramuscular meglumine antimoniate in patients of cutaneous leishmaniasis. Study Design:  Randomized Control Trial.
Hina Mazhar, Faiz -ul- Hassan, Mansoor Dilnawaz   +2 more
doaj   +2 more sources

First Report on Infant Acute Urticaria after Mother’s Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report

Iranian Journal of Public Health, 2016
Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate ...
Omid MOZAFARI, Seyed Afshin SHOROFI, Seyde Sedighe YOUSEFI   +2 more
doaj  

High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls

Memorias do Instituto Oswaldo Cruz, 2003
We analyzed data from historical controls treated with meglumine antimoniate to compare the frequency of adverse events observed in patients with cutaneous leishmaniasis treated with the same dose of meglumine antimoniate contaminated with heavy metals ...
Gustavo Adolfo Sierra Romero, Érico Marlon de Moraes Flores, Elza Ferreira Noronha, Vanize de Oliveira Macêdo   +3 more
doaj   +1 more source

Comparison of survival rate of intramuscular and intralesional prescription of meglumine antimoniate over time.

, 2019
Comparison of survival rate of intramuscular and intralesional prescription of meglumine antimoniate over time.
Fatemeh Sharifi (3496619), Rajender S. Varma (1407823), Mohammad Reza Aflatoonian (525156), Hamid Sharifi (525162), Mehdi Mohebali (62368), Mehrdad Khatami (6831896), Nasir Arefinia (6831899), Mohammad Mehdi Gouya (572523), Pooya Ghasemi Nejad Almani (4960441), Ahmad Khosravi (525161), Amireh Heshmatkhah (4960435), Saeideh Farajzadeh (6831905), Alireza Fekri (6831902), Ali Khamesipour (62371), Behnaz Aflatoonian (525159), Abbas Aghaei Afshar (6831893), Mehdi Bamorovat (4836909), Zahra Babaei (806332), Ehsan Salarkia (6831890), Mohammad Reza Shirzadi (3092862), Mohammad Ali Mohammadi (4960429), Iraj Sharifi (344800)   +21 more
core   +1 more source

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol

Parasites & Vectors, 2015
Background Visceral leishmaniosis is a potentially life-threatening illness caused by a protozoan parasite of the genus Leishmania. It is found mainly in areas where both the parasite and its vector are endemic and is one of the most challenging ...
Laura Manna, Raffaele Corso, Giorgio Galiero, Anna Cerrone, Paolo Muzj, Angelo Elio Gravino   +5 more
doaj   +1 more source

Response to treatment of cutaneous leishmaniasis with intralesional chloroquine vs intralesional meglumine antimoniate

, 2016
Background In Pakistan, cutaneous leishmaniasis (CL) is mostly caused by Leishmania major. For simple lesions which are few in number and where there is no risk of disfigurement or joint mobility restriction, topical application or local treatment e.g ...
Rifat Yasmin, Syed Afaq Ahmad, Ikramullah Khan   +2 more
core   +1 more source

LEUCOGRAMA E METABOLISMO OXIDATIVO DOS NEUTRÓFILOS DE CÃES COM LEISHMANIOSE VISCERAL ANTES E APÓS O TRATAMENTO COM ANTIMONIATO DE MEGLUMINA E ALOPURINOL

Ciência Animal Brasileira, 2010
Leukogram and neutrophil oxidative metabolism fromdogs with visceral leishmaniasis (VL) were compared before andafter treatment with meglumine antimoniate (AM) and with anassociation of meglumine antimoniate and allopurinol (AMA).The results obtained ...
Paulo César Ciarlini, Taiana Carvalho Valadares, Fabiana Augusta Ikeda-Garcia, Mary Marcondes, Valéria Marçal Félix de Lima   +4 more
doaj  

Incidence of adverse events recorded in 1,210 pediatric patients treated with meglumine antimoniate.

, 2013
Incidence of adverse events recorded in 1,210 pediatric patients treated with meglumine antimoniate.
Raida Petrela (361878), Eli Foto (361881), Luigi Gradoni (361885), Ferit Zavalani (361883), Loreta Kuneshka (361879)   +4 more
core   +1 more source

Comparison of Efficacy of Intralesional Metronidazole Versus Intralesional Meglumine Antimoniate in Patients of Cutaneous Leishmaniasis

Pakistan Armed Forces Medical Journal
Objective: To compare the effectiveness of intralesional Metronidazole versus intralesional Meglumine antimoniate  in the treatment of cutaneous leishmaniasis. Study Design: Quasi experimental study.
Raisa Khan Gul, Sameena Kausar, Tehseen Naveed, Sumyra Saleem, Sarah Riaz, Ghazala Said   +5 more
doaj   +1 more source

First report on ototoxicity of meglumine antimoniate

, 2017
Introdução: Antimoniais pentavalentes são os fármacos de primeira escolha no tratamento da leishmaniose tegumentar. Dados de ototoxicidade relacionados a tais fármacos são escassos na literatura, o que nos levou a desenvolver um estudo de funções cócleo ...
Salgueiro, Mariza de Matos, Torraca, Tania Salgado de Sousa, Vargas, Mirian Catherine Melgares, Saheki, Maurício Naoto, Schubach, Armando Oliveira, Barcelos, Renata Oliveira de, Valete-Rosalino, Claudia Maria, Araujo-Melo, Maria Helena, Martins, Ana Cristina da Costa, Moreira, Joao Soares, Bezerra, Debora Cristina de Oliveira, Melo-Ferreira, Vanessa de, Braga, Frederico Pereira Bom   +12 more
core